Adaptive Biotechnologies Corp vs Cassava Sciences Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Adaptive Biotechnologies Corp is far larger — about 84.6× Cassava Sciences Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | FLNA | |
|---|---|---|
Market Cap | $4.04B | $47.75M |
Sector | Health | Health |
52-Week High | $25.45 | $4.64 |
52-Week Low | $12.30 | $0.87 |
Enterprise Value | $4.10B | -$34.93M |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →